Login to Your Account



Cellectis-Cellartis Join Forces, Focus on Personalized Medicine

By Nuala Moran
BioWorld Today Correspondent

Friday, November 4, 2011

LONDON – Cellectis SA today completes the acquisition of Europe's leading private stem cell company, the Swedish/British Cellartis AB, owner of 30 proprietary stem cell lines, in a cash and shares deal valued at €30 million (US$41.4million).

The deal will fuse Cellectis' expertise in the creation of induced pluripotent stem (iPS) cells from adult somatic cells with Cellartis' skills in differentiating embryonic pluripotent stem cells into specific cell types, including cardiomyocytes and hepatocytes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription